Source link : https://www.newshealth.biz/health-news/vedolizumab-reduces-postoperative-crohns-disease-recurrence/
TOPLINE: Vedolizumab treatment within 4 weeks of ileocolonic resection outperformed placebo in preventing postoperative endoscopic recurrence of Crohn’s disease in patients with at least one risk factor for recurrence, the REPREVIO trial found. METHODOLOGY: Researchers conducted the multicenter REPREVIO trial to evaluate the efficacy and safety of vedolizumab, an α4β7 integrin antibody, in preventing the […]
Author : News Health
Publish date : 2024-12-26 10:49:34
Copyright for syndicated content belongs to the linked Source.